The clinical study is a Phase Ib placebo-controlled, single-center dose ranging study. The primary objectives are to evaluate safety and tolerability and to determine preliminary pharmacokinetics of AZX100 in healthy adult subjects undergoing elective skin punch biopsy. Approximately 40 subjects are planned for treatment.
Randolph Steer, president of OrthoLogic, said: “We are pleased that dosing has begun in the second study for our AZX100 Phase I human clinical trial program in dermal scarring.
“The goal of this program for AZX100 is to develop a safe and effective medication for an unmet market need. We had previously stated this Phase Ib study would begin during third quarter 2008, and we are on track with our announced timelines.”